| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
IND Filing example | IND | — | Subscribe to access the data. | Small Molecules | Hematologic System | ||
IND Filing example | IND | — | Subscribe to access the data. | Small Molecules | Hematologic System | ||
IND Filing example | IND | — | Subscribe to access the data. | Small Molecules | Hematologic System |
Recent Updates
Recently added Catalysts
Metagenomi Therapeutics, Inc.
$1.23
-0.05 (-4.07%)
Market Cap
46.31 M
EPS
-2.28
P/E Ratio
-
Value Trade
203.55 K
SEC Financials
Q1 2026Dilution Risk
25%Revenue
1.25 M
R&D Expenses
19.30 M
Operating CF
-21.18 M
Total Assets
196.95 M
Total Liabilities
59.17 M
Equity
137.78 M
1.65 %
Week
-6.82 %
1 Month
-8.89 %
3 Month
-19.61 %
6 Month
-86.83 %
5 Year
-86.83 %
All Time
Cash Data
Cash Position
140.16 M
Monthly Burn
7.06 M
Runway
17.1 mo
Burn Trend
StableSEC Filing
May 11, 2026
Overview
Volume
151.51 K
52 Week Range
1.13 - 3.95
% held by Insiders
21.01 %
% held by Institutions
17.4 %
Enterprise Value
-93.86 M
Total Shares
37.65 M
Short %
5.19 %
Float Shares
22.51 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Metagenomi Therapeutics, Inc.
110Total events
3Upcoming
4Tier-1 (high impact)
2023 – 2027Coverage
Upcoming catalysts 2
TBD
T2IND Submission
Subscribe to view catalyst details
TBD
T2Trial Initiation
Subscribe to view catalyst details
Event history 2
TBD
◆Oral PresentationPresentation
Subscribe to view catalyst details
TBD
▲PublicationMG119Presentation
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2024-12-09 | MGX-001 (hemophilia A gene editing investigational therapy) | Pre-clinical data readout | Pre-clinical | — | – | – | – |
2024-12-09 | MGX-001 (hemophilia A gene editing investigational therapy) | Pre-clinical data readout | Pre-clinical | — | – | – | – |
2024-12-09 | MGX-001 (hemophilia A gene editing investigational therapy) | Pre-clinical data readout | Pre-clinical | — | – | – | – |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
MGX-001 | hemophilia A | — | 2024-12-09 | FVIII activity months 13 16: 71, 7, 27; FVIII activity months 3 6: 76, 8, 30; FVIII activity months 7 12: 77, 8, 32; FVIII levels at 16 5 months: 72, 9, 30; gene integration frequency: 0.7, 1.3, 3.1 Read More | Metagenomi Presents Updated Preclinical Data in Hemophilia A at American Society of Hematology (ASH) 66th Annual Meeting Therapeutically relevant levels of Factor VIII (FVIII) activity sustained in ongoing nonhuman prima Read More | |
MGX-001 | hemophilia A | — | 2024-12-09 | FVIII activity months 13 16: 71, 7, 27; FVIII activity months 3 6: 76, 8, 30; FVIII activity months 7 12: 77, 8, 32; FVIII levels at 16 5 months: 72, 9, 30; gene integration frequency: 0.7, 1.3, 3.1 Read More | Metagenomi Presents Updated Preclinical Data in Hemophilia A at American Society of Hematology (ASH) 66th Annual Meeting Therapeutically relevant levels of Factor VIII (FVIII) activity sustained in ongoing nonhuman prima Read More | |
MGX-001 | hemophilia A | — | 2024-12-09 | FVIII activity months 13 16: 71, 7, 27; FVIII activity months 3 6: 76, 8, 30; FVIII activity months 7 12: 77, 8, 32; FVIII levels at 16 5 months: 72, 9, 30; gene integration frequency: 0.7, 1.3, 3.1 Read More | Metagenomi Presents Updated Preclinical Data in Hemophilia A at American Society of Hematology (ASH) 66th Annual Meeting Therapeutically relevant levels of Factor VIII (FVIII) activity sustained in ongoing nonhuman prima Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in MGX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
MGX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
MGX▼ -4.1%today
Metagenomi Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results
Metagenomi Therapeutics is progressing towards submitting an investigational new drug application for MGX-001, aimed at treating hemophilia A, expected in the fourth quarter of 2026. The company reported having $120.7 million in cash and equivalents as of June 30, 2026, ensuring a solid financial runway for its upcoming clinical endeavors.
Read more →MGXMetagenomi Therapeutics, Inc. to Present at the Jefferies Global Healthcare Conference
Metagenomi Therapeutics, Inc. announced that CEO Jian Irish will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 4, 2026. The company focuses on developing curative genetic medicines using its proprietary genome editing technologies. Its lead program, MGX-001, aims to provide a one-time treatment for hemophilia A, potentially setting a new standard of care.
Read more →MGXMetagenomi Therapeutics Reports Business Updates and First Quarter 2026 Financial Results On track for regulatory submission of MGX-001 to advance global clinical program, including investigational new drug application (
Metagenomi Therapeutics has reported its business updates and first-quarter financial results for 2026. The company is on schedule for the regulatory submission of its MGX-001 program aimed at treating hemophilia A, with plans to initiate clinical trials in 2027. A recent publication in Nature has showcased the promising capabilities of their proprietary MG119-28 CRISPR nuclease. Metagenomi currently has a strong cash reserve of $140.2 million, which is projected to sustain its operations until at least late 2027.
Read more →MGXMetagenomi Therapeutics, Inc. Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Genome Editing Efficiency
Metagenomi Therapeutics, Inc. announced a publication in Nature Structural & Molecular Biology detailing the compact CRISPR nuclease MG119-28, which exhibits enhanced genome editing efficiency. The study reveals that MG119-28's superior structural stability and stable guide RNA contribute to its effectiveness. The company aims to leverage these findings to advance gene editing applications beyond liver-related diseases.
Read more →MGXMetagenomi Therapeutics Reports Business Updates and Full Year 2025 Financial Results Completed pre-IND meeting following MGX-001 preclinical data demonstrating curative FVIII activity in non-human primates (NHPs) and re
Metagenomi Therapeutics, Inc. (MGX) announced significant advancements in its pipeline, including the completion of a pre-IND meeting for their MGX-001 hemophilia A program, supporting potential clinical trials in 2027. The company reported a solid financial position with $160.8 million in cash, indicating a runway through 2027. A corporate name change was also announced, aligning with the firm’s strategic evolution in the genetic medicine space. The preclinical data demonstrated curative FVIII activity in non-human primates, which positions MGX-001 as a competitive treatment option.
Read more →MGX▲ +6.4%on this news
Metagenomi Therapeutics, Inc. to Present at the 46th Annual TD Cowen Healthcare Conference
Metagenomi Therapeutics, Inc. announced its participation in the 46th Annual TD Cowen Healthcare Conference, where CEO Jian Irish will discuss the company's advancements. The focus will be on their lead program, MGX-001, which aims to provide a curative treatment for hemophilia A. The company is leveraging its proprietary technologies to expand its pipeline of genetic medicines.
Read more →MGXMetagenomi Announces Corporate Name Change to Metagenomi Therapeutics, Inc. and Highlights Recent Business Milestones and 2026 Corporate Outlook
Metagenomi Therapeutics, Inc. has announced its corporate name change to reflect its focus on advanced gene-editing technologies. The company highlighted significant milestones achieved in 2025, particularly with its lead program MGX-001 for hemophilia A, which demonstrated promising preclinical results. Anticipated IND/CTA submissions are planned for late 2026, with a cash runway expected to last through 2027.
Read more →MGXxfeff; Metagenomi Announces Corporate Name Change to Metagenomi Therapeutics, Inc. and Highlights Recent Business Milestones and 2026 Corporate Outlook New name reflects the Company's strategic evolution focused on later
Metagenomi Therapeutics, Inc. has officially changed its name to reflect its focus on later-stage preclinical assets, particularly in the hemophilia A program, MGX-001. The company has achieved significant milestones, including promising preclinical data showing curative activity in non-human primates, positioning itself for IND/CTA submissions in late 2026. With an expected cash runway until Q4 2027, Metagenomi aims to accelerate the development of its gene-editing therapies while preparing for human studies in 2027. Additionally, the company continues to evaluate collaborations in other therapeutic areas, demonstrating a strategic commitment to addressing unmet medical needs.
Read more →MGX▼ -8.6%on this news
Metagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature Conference
Metagenomi, Inc. announced it will present preclinical data on APOC3 at the upcoming Nature Conference. This collaboration with Ionis Pharmaceuticals focuses on a CRISPR/Cas-mediated approach to treat severe hypertriglyceridemia. The presentation will be delivered by Alan Brooks, PhD, on December 8, 2025, in Boston, MA.
Read more →MGXMetagenomi to Present at Jefferies Global Healthcare Conference in London
Metagenomi, Inc. announced that its CEO, Jian Irish, will present at the Jefferies Global Healthcare Conference in London on November 20, 2025. The company focuses on in vivo genome editing and has developed proprietary technologies aimed at creating curative genetic medicines. MGX-001, their lead program targeting hemophilia A, has demonstrated promising preclinical results. Metagenomi is also exploring other indications, highlighting its commitment to expanding its product pipeline.
Read more →MGX▼ -15.5%on this newsshared move
Metagenomi Reports Third Quarter 2025 Financial Results and Announces Strategic Pipeline Prioritization and Leadership Updates
Metagenomi reported its third quarter 2025 financial results, highlighting positive preclinical data for its MGX-001 hemophilia A program. The company is prioritizing its later-stage preclinical pipeline and has undergone a workforce reduction of 25% to optimize operations. Jian Irish has been appointed as the new CEO, succeeding Brian Thomas, who will remain on the Board.
Read more →MGX▼ -15.5%on this newsshared move
Metagenomi Presents New Preclinical Data from MGX-001 Hemophilia A Program Supporting Advancement into Clinical Development
Metagenomi has reported promising preclinical data for its MGX-001 hemophilia A program, demonstrating curative FVIII activity in non-human primates. The company plans to advance MGX-001 into clinical development, with regulatory submissions expected by the end of 2026. This approach aims to provide a one-time treatment that restores the body's ability to produce FVIII.
Read more →MGXMetagenomi Reports Business Updates and Second Quarter 2025 Financial Results
Metagenomi, Inc. reported its financial results for Q2 2025, highlighting a robust cash position of $205 million, which is expected to support operations until 2027. The company is advancing its MGX-001 program for hemophilia A and collaborating with Ionis on cardiometabolic indications. Additionally, Metagenomi presented three abstracts at the ASGCT, showcasing its gene editing technologies.
Read more →MGXMetagenomi Appoints Laurence Reid, PhD to its Board of Directors
Metagenomi, Inc. has appointed Laurence Reid, PhD, to its Board of Directors, enhancing its leadership team. Dr. Reid brings extensive experience in biotech and business development, which is expected to support the company's growth and innovation in gene editing technologies. His appointment comes at a crucial time as Metagenomi aims to advance its therapeutic pipeline.
Read more →MGX▼ -6.2%on this news
Metagenomi Presents Data Highlighting Advancements in Next-Generation Genome Editing Technologies at ASGCT Annual Meeting 2025
Metagenomi presented significant advancements in genome editing technologies at the ASGCT Annual Meeting 2025. The company showcased its capabilities in extrahepatic gene editing and site-specific integration of large therapeutic genes. These innovations aim to improve treatment options for neurological disorders and other diseases caused by genetic mutations.
Read more →MGXMetagenomi Reports Business Updates and First Quarter 2025 Financial Results - Nonhuman primate (NHP) study in hemophilia A demonstrated therapeutically relevant factor VIII (FVIII) activity with durable response through
Metagenomi, Inc. has reported robust financial results for the first quarter of 2025, showcasing impressive durability of factor VIII activity in their hemophilia A program during a nonhuman primate study. The study reported sustained therapeutic levels of FVIII activity lasting approximately 19 months, with no major safety concerns. The company remains well-funded, having $226 million available, which is projected to support operations through 2027. Advances in their gene editing technologies are underscored by a recent publication in Nature Communications regarding their metagenomics platform.
Read more →MGX▲ +8.1%on this news
Metagenomi to Present at Upcoming Scientific Meetings
Metagenomi, Inc. announced its participation in two upcoming scientific meetings, including an oral presentation at TIDES USA 2025 and three poster presentations at the ASGCT 2025 Annual Meeting. The presentations will focus on advanced gene editing technologies and their applications in therapeutic settings. This highlights Metagenomi's commitment to innovation in precision genetic medicine.
Read more →MGXMetagenomi Reports Business Updates and Full Year 2024 Financial Results Hemophilia A presentation at American Society of Hematology (ASH) 66th Annual Meeting demonstrated sustained Factor VIII (FVIII) activity in nonhum
Metagenomi, a precision genetic medicines company, has released its full year 2024 financial results and business updates. Significant achievements include demonstrating sustained Factor VIII activity for over 16 months in nonhuman primate studies and advancing their MGX-001 program for hemophilia A. The company has made progress in collaboration with Ionis Pharmaceuticals, with plans to nominate development candidates in 2025. Additionally, Metagenomi remains well-capitalized with over $248 million in cash to support its future operations.
Read more →MGX▼ -6.8%on this newsshared move
Metagenomi Announces Publication in Nature Communications on Large Gene Integration Advances Using Novel, Compact CRISPR-associated transposase (CAST) Systems
Metagenomi has published findings on its novel CAST system in Nature Communications, demonstrating successful targeted integration of large genes into human cells. This first-in-class technology simplifies the delivery of therapeutic genes, potentially addressing complex genetic diseases. Future advancements in this area are anticipated in 2025, further enhancing gene editing capabilities.
Read more →MGX▼ -6.2%on this news
Metagenomi to Present at TD Cowen's 45th Annual Health Care Conference
Metagenomi, Inc. will present at TD Cowen's 45th Annual Health Care Conference on March 5, 2025. CEO Brian C. Thomas will participate in a fireside chat, and the company will hold one-on-one investor meetings. The event highlights Metagenomi's commitment to developing curative therapeutics using its proprietary gene editing technology.
Read more →MGXMetagenomi Highlights Progress Across Therapeutic Portfolio and Outlines Anticipated Milestones
Metagenomi, Inc. has announced notable progress in its therapeutic development programs, particularly with the potential curative candidate MGX-001 for hemophilia A. The company anticipates critical regulatory interactions and milestones in 2025 and 2026. Additionally, advancements in gene editing technologies are expected to enhance its therapeutic strategies, while a stable cash runway is projected to support operations into 2027. The collaboration with Ionis on cardiometabolic conditions is also reported to be progressing well.
Read more →MGXrd Annual J.P. Morgan Healthcare Conference Nasdaq: MGX January 2025 Unlocking 4 Billion Years of Microbial Evolution to Create Curative Genetic Medicines Forward Looking Statements This presentation includes forward-loo
Metagenomi is set to present at the 43rd Annual J.P. Morgan Healthcare Conference, focusing on its innovative use of metagenomics to develop curative genetic medicines. The company has recently shown promising results in sustaining Factor VIII activity in non-human primates, suggesting advancements in their hemophilia A program. However, the presentation also emphasizes the inherent risks related to regulatory approvals and the competitive nature of the industry.
Read more →MGXMetagenomi Announces New Appointment to its Board of Directors
Metagenomi, Inc., a precision genetic medicines company, announced the appointment of Eric Bjerkholt as a new member of its Board of Directors, effective January 27, 2025. Bjerkholt, currently the CFO of Mirum Pharmaceuticals, brings a wealth of experience from his previous roles within the biopharma sector. His expertise is expected to support Metagenomi in advancing its gene editing technologies and therapeutic developments. This move reflects the company's strategic goals in the gene editing industry.
Read more →MGX▼ -6.4%on this news· ran to -16% by day 3
Metagenomi to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Metagenomi, a precision genetic medicines company, announced that CEO Brian C. Thomas will present at the J.P. Morgan Healthcare Conference on January 15, 2025. The company aims to leverage its proprietary gene editing tools, derived from metagenomics, to develop curative therapies. A live webcast of the presentation will be available on their investor site. This participation highlights Metagenomi's commitment to advancing gene editing technology and addressing genetic mutations effectively.
Read more →MGX▼ -5.7%on this news· ran to -26% by day 3
Metagenomi Presents Highly Specific and Efficient Genome Editing Tools at Nature Conference “RNA at the Bench and Bedside IV”
Metagenomi recently presented its advanced genome editing tools at the Nature Conference, emphasizing the high specificity and efficiency of its proprietary MG29-1 nuclease and Adenine Base Editor. Both tools showed no detectable off-target effects or translocations in preclinical tests, supporting their potential for therapeutic applications. The presentation highlights the company's commitment to safety and efficacy in developing precision genetic medicines, particularly for conditions like hemophilia A. Metagenomi aims to leverage its metagenomics platform to further advance its gene editing capabilities toward clinical use.
Read more →MGX▲ +125.4%on this newsshared move
Metagenomi Presents Updated Preclinical Data in Hemophilia A at American Society of Hematology (ASH) 66th Annual Meeting Therapeutically relevant levels of Factor VIII (FVIII) activity sustained in ongoing nonhuman prima
Metagenomi showcased promising preclinical data for its hemophilia A program at the ASH 66th Annual Meeting, highlighting sustained therapeutic levels of Factor VIII (FVIII) activity over more than 16 months in nonhuman primates. The lead candidate, MGX-001, demonstrated superior FVIII activity compared to the wild type, suggesting a potential paradigm shift for treatment. The company plans to file for an Investigational New Drug (IND) application in 2026 and emphasizes the safety of its gene-editing approach, with no identified off-target effects to date.
Read more →MGXMetagenomi Reports Business Updates and Third Quarter 2024 Financial Results Initiating IND-enabling activities for MGX-001 development candidate (DC) in hemophilia A; Achieved durable Factor VIII activity levels over tw
Metagenomi provided updates on its business and financial results for the third quarter of 2024, highlighting the initiation of IND-enabling activities for its MGX-001 candidate aimed at hemophilia A. The company achieved significant results in nonhuman primate studies, demonstrating sustained Factor VIII activity. With a strong financial position, Metagenomi plans to continue its development pipeline, including anticipated collaborations leading to further product candidates by 2025. The firm also plans to present new preclinical data at major upcoming conferences.
Read more →MGXMetagenomi To Present New Preclinical Hemophilia A Data at American Society of Hematology (ASH) 66th Annual Meeting
Metagenomi, Inc. announced that its abstract regarding the lead candidate MGX-001, aimed at treating hemophilia A, has been accepted for oral presentation at the ASH 66th Annual Meeting. The presentation will focus on preclinical data demonstrating durable expression of the Factor VIII gene in nonhuman primates. This research aims to address the limitations of existing therapies, which are not curative and do not prevent breakthrough bleeding. The event is scheduled for December 9, 2024, in San Diego.
Read more →MGXMetagenomi Presents Novel, Highly Specific and Efficient Adenine Base Editors for Broad Genome Editing at ESGCT
Metagenomi has introduced advanced Adenine Base Editors (ABEs) during the ESGCT 31st Annual Congress, showcasing their efficacy in genome editing. The ABEs achieved over 95% targetability and protein knockdown in primary T-cells, while exhibiting excellent specificity and tolerability without adverse effects. Metagenomi's platform presents a versatile toolkit for developing future therapeutic applications in gene editing, aimed at correcting genetic mutations across a broad spectrum. The company continues to focus on enhancing in vivo genome editing programs and potential partnerships for ex vivo cell therapy applications.
Read more →MGXMetagenomi Presents Compact SMART Editing Platform at AIChE 7th International Conference on CRISPR Technologies
Metagenomi, Inc. presented its compact SMART editing platform at the AIChE 7th International Conference on CRISPR Technologies. The presentation highlighted advancements in their adenine base editors, which are capable of being packaged into standard adeno-associated virus (AAV) vectors. This development addresses the challenges of delivering gene editing components to tissues beyond the liver, enhancing the potential treatment of neuromuscular diseases. The company utilizes metagenomics and AI-driven techniques to optimize their gene editing toolbox aimed at correcting genetic mutations.
Read more →MGXMetagenomi to Present at Chardan's 8th Annual Genetic Medicines Conference
Metagenomi, Inc. will present at Chardan's 8th Annual Genetic Medicines Conference, featuring a fireside chat and a panel discussion on genome editing. CEO Brian Thomas and other executives will discuss the company’s advancements in precision genetic therapies. The event is scheduled for September 30, 2024, and details will be available via a webcast. Metagenomi aims to develop innovative therapeutics using its unique metagenomics-derived gene editing toolbox.
Read more →MGXMetagenomi Announces Preclinical Data for Lead Hemophilia A Program Demonstrating Durable Factor VIII (FVIII) Activity Levels through Twelve Months Twelve-month durability data from Metagenomi's ongoing nonhuman primate
Metagenomi has announced encouraging twelve-month durability data for its lead hemophilia A gene therapy candidate, MGX-001, which showed consistent FVIII activity levels in nonhuman primates. The company is moving forward with plans to file an Investigational New Drug application by 2026. The treatment demonstrated good tolerability with no major adverse effects observed. These developments mark a significant step for Metagenomi in the competitive gene therapy landscape for hemophilia A.
Read more →MGXMetagenomi Presents AI-Enabled Advancements of SMART Editing Platform at the Cold Spring Harbor Laboratory CRISPR Frontiers Conference
Metagenomi presented advancements in its AI-enabled SMART editing platform at the Cold Spring Harbor Laboratory CRISPR Frontiers Conference. The company demonstrated robust genome editing activity with compact SMART nucleases, which are designed for compatibility with various delivery technologies. CEO Brian C. Thomas emphasized the significance of novel gene editing tools to overcome limitations in current systems. The use of metagenomics alongside AI methods positions Metagenomi to develop highly effective gene editing tools aimed at addressing a range of genetic diseases.
Read more →MGX▼ -5%on this newsshared move
Metagenomi to Participate in Upcoming Investor Conferences
Metagenomi, Inc. (Nasdaq: MGX), a company focused on precision genetic medicines, announced its participation in two upcoming investor conferences. The Wells Fargo Healthcare Conference will feature a fireside chat with key executives including the CEO and CMO. Additionally, Metagenomi will present at the H.C. Wainwright 26th Annual Global Investment Conference, showcasing its innovative gene editing technology and therapeutic potential. Live webcasts of these presentations will be available on the company's investor website.
Read more →MGXMetagenomi Reports Business Updates and Second Quarter 2024 Financial Results Declared development candidate MGX-001 for the treatment of hemophilia A; plans to present 12-month NHP durability study data in September 202
Metagenomi has announced the declaration of MGX-001 as its lead development candidate for treating hemophilia A and plans to present data from a 12-month nonhuman primate durability study in September 2024. Additionally, the company has achieved a regulatory milestone with its partner Affini-T and reported strong financial results with approximately $299.9 million in cash leading to a projected runway into 2027. All Wave 1 collaboration programs with Ionis have advanced into lead optimization phase, with expectations to nominate further development candidates in the coming years.
Read more →MGXMetagenomi to Present at the 2024 Jefferies Global Healthcare Conference
Metagenomi, a precision genetic medicines company, announced its CEO, Brian C. Thomas, will present at the 2024 Jefferies Global Healthcare Conference on June 5. The company will showcase its proprietary gene editing tools designed to develop curative therapies. Additionally, Metagenomi will engage in one-on-one investor meetings during the conference. The event signifies the company's commitment to advancing genetic medicine and attracting potential investment.
Read more →MGXMetagenomi Presents Data at Scientific Conferences and First Quarter 2024 Financial Results Late breaking presentation at World Federation of Hemophilia (WFH) World Congress on investigational development program in Hemo
Metagenomi recently showcased significant advancements in its gene editing technologies during scientific conferences and reported its Q1 2024 financial results. At the WFH World Congress, promising data on Factor VIII expression for Hemophilia A was presented, with a development candidate nomination expected by mid-2024. The company ended the first quarter with $327.4 million in cash, projecting financial stability through 2027. Additionally, Metagenomi regained full rights to its base editing and RNA-mediated integration systems, positioning itself to address various genetic disorders.
Read more →MGXMetagenomi to regain full development rights to its wholly-owned base editing and RIGS systems
Metagenomi, Inc. has announced that it has regained full global rights to its gene editing technologies, including base editors and RNA-mediated integration systems (RIGS), from Moderna, with whom it previously collaborated. The termination of their agreement will allow Metagenomi to further develop its gene editing toolbox independently. CEO Brian Thomas stated this provides an opportunity to address major health concerns with new therapeutic approaches. Metagenomi plans to enhance its capabilities and expand its development reach following this strategic shift.
Read more →MGXNasdaq listed (MGX) Business Update Call May 1st, 2024, 5pm ET Unlocking 4 Billion Years of Microbial Evolution to Create Curative Genetic Medicines Forward Looking Statements This presentation includes forward-looking s
Metagenomi (MGX) provided a business update highlighting key developments expected in 2024, including progress in hemophilia A treatments and advancements in gene editing technologies. The company has regained full rights to its Base Editing and RIGS technology, allowing it to advance its pipeline programs. The presentation emphasized the ongoing potential of these technologies in addressing genetic diseases and the company's dedication to innovation.
Read more →MGXMetagenomi Reports Business Updates and Full Year 2023 Financial Results Demonstrated nonhuman primate proof of concept in Hemophilia A program; progressing towards Development Candidate nomination by mid-year; 12-month
Metagenomi, Inc. announced its business updates and full-year financial results for 2023, highlighting successful proof of concept for its Hemophilia A program in nonhuman primates. The company plans to nominate a Development Candidate by mid-2024 and present 12-month durability data later in the year. Additionally, Metagenomi has secured funding from a recent IPO, providing resources for ongoing development initiatives. Advanced gene editing technologies such as the CRISPR-associated transposase (CAST) system and ultra-small base editing systems are also being progressed.
Read more →MGXMetagenomi to Participate in the 44th Annual Cowen Healthcare Conference
Metagenomi, Inc. (MGX), a precision genetic medicines company, will participate in the 44th Annual Cowen Healthcare Conference on March 6, 2024. CEO Brian C. Thomas is scheduled to be part of a panel on 'Emerging Genetic Therapy Approaches.' The event signifies Metagenomi's commitment to discussing innovative therapeutic strategies utilizing their comprehensive metagenomics-derived gene editing toolset. A live webcast of the panel will be accessible on the company's website, with an archived replay available for 30 days post-event.
Read more →MGXMetagenomi Announces Closing of Initial Public Offering
Metagenomi, Inc. has successfully closed its initial public offering, selling 6,250,000 shares at $15.00 each, raising around $93.75 million. The shares began trading on the Nasdaq Global Select Market under the ticker symbol 'MGX' on February 9, 2024. The offering secured backing from several prominent financial firms, including J.P. Morgan and Jefferies. Metagenomi specializes in precision genetic medicines, leveraging a proprietary toolbox for gene editing to develop innovative therapeutics.
Read more →MGXMetagenomi Announces Pricing of Initial Public Offering
Metagenomi, Inc. has announced the pricing of its initial public offering, offering 6,250,000 shares at $15.00 each, aiming to raise approximately $93.75 million. The shares are set to trade on the Nasdaq Global Select Market under the ticker symbol 'MGX' starting February 9, 2024. The offering, which includes an option for underwriters to purchase additional shares, underscores the company's commitment to advancing precision genetic medicines derived from metagenomics. The offering process will close on February 13, 2024, pending customary conditions.
Read more →Competitive Position
How MGX ranks across every disease it competes inCompetitive Position is a premium feature
See how MGX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial